A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324

Completed · Phase 1

Conditions studied: Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration

In brief

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324

Key facts

Study ID
NCT07484074
Run by
Ollin Biosciences, Inc.
People needed
164
Starts
2025-02-12
Expected to finish
2025-12-09
Last updated by the study team
2026-03-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.